Work

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2574

Authors: Jordan Berlin, Ramesh K. Ramanathan, John H. Strickler, Deepa Suresh Subramaniam, Herbert Hurwitz, Yoon-Koo Kang, Tae-You Kim, Stacie Peacock Shepherd, Hao Xiong, Robert Hetman, Caroline Nickner, Matthew W. Dudley, Vincent L. Giranda, Heinz-Josef Lenz

Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Translational Genomics Research Institute, Duke Medical Center, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Asan Medical Center, University of Ulsan, Seoul National University, Seoul National University Hospital, AbbVie (United States), AbbVie Canada (Canada), University of Southern California, USC Norris Comprehensive Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2766236248

Cites:

Cited by: 8

Related to: 10